15. Recombinant Adenoviruses for Vaccination

  1. W. John W. Morrow PhD, DSc, FRCPath4,
  2. Nadeem A. Sheikh PhD5,
  3. Clint S. Schmidt PhD6 and
  4. D. Huw Davies PhD7
  1. Nelson Cesar Di Paolo PhD1,2,
  2. Dmitry Shayakhmetov PhD1,2 and
  3. André Lieber MD, PhD1,3

Published Online: 20 JUN 2012

DOI: 10.1002/9781118345313.ch15

Vaccinology: Principles and Practice

Vaccinology: Principles and Practice

How to Cite

Di Paolo, N. C., Shayakhmetov, D. and Lieber, A. (2012) Recombinant Adenoviruses for Vaccination, in Vaccinology: Principles and Practice (eds W. J. W. Morrow, N. A. Sheikh, C. S. Schmidt and D. H. Davies), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118345313.ch15

Editor Information

  1. 4

    Seattle, WA, USA

  2. 5

    Dendreon Corporation, Seattle, WA, USA

  3. 6

    NovaDigm Therapeutics, Inc., Grand Forks, ND, USA

  4. 7

    University of California at Irvine, Irvine, CA, USA

Author Information

  1. 1

    Department of Medicine, Division of Medical Genetics, USA

  2. 2

    University of Washington, Seattle, WA, USA

  3. 3

    Department of Pathology, University of Washington, Seattle, WA, USA

Publication History

  1. Published Online: 20 JUN 2012
  2. Published Print: 3 AUG 2012

ISBN Information

Print ISBN: 9781405185745

Online ISBN: 9781118345313

SEARCH

Keywords:

  • adenovirus;
  • prime-boost;
  • vector;
  • capsid;
  • transgene

Summary

Recombinant adenovirus vectors (Ads) are used as delivery vehicles either to express an antigen-encoding gene or to transfer an antigen protein in the context of the Ad capsid. Recent preclinical studies indicate that the combination of Ad with other vaccine platforms in heterologous prime-boost regimens has the potential to induce protective immunity, and the use of adjuvants or inhibition of regulatory T cells might further increase the efficacy of these approaches. A major problem with the currently used Ads is pre-existing anti-Ad immunity in humans and the induction of strong anti-Ad immune responses that can interfere with vaccination. Recent efforts in the understanding of the interaction of Ad with the host and the development of new Ad vectors based on rare serotypes can potentially address these problems.

In this chapter, we will present principal approaches and considerations for the use of Ad as a vaccine, and discuss recent applications of Ads for prevention and treatment of infectious diseases and cancer.